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ABSTRACT 
Zolmitriptan known for its anti-migrain activity. The fast dissolving oral film of drug Zolmitriptan was designed in order to relief and ease the 
pain caused to patient suffering from Migraine followed by nausea, vomiting and sensitivity towards light/sound. The oral fil m was prepared 
using HPMC (Hydroxy Propyl Methyl Cellulose) as polymer and PEG as plasticizer by solvent casting method. The aim of preparing fast  
dissolving oral film of drug zolmitriptan was to have better Bioavability, quick onset of action (quick relief) and to prevent first pass 
metabolism. Films were subjected to physicochemical characterization such as thickness, weight variation, folding endurance drug content and 
were found to be satisfactory. The surface pH of all the films was found to be neutral. The results of the studies indicated that HPMC E50 could 
be used as a film forming polymer for the formulation. All the films prepared using HPMC E50 showed acceptable mechanical pro perties. On the 
basis of tensile strength, drug content and in vitro dissolution, formulation F3 was found to be the promising formulation showing better 
strength and good drug release profile. Also this formulation was stable for a period of 45 days with no significant change in drug content and 
drug release profile. Thus it could be said that the fast dissolving sublingual film of Zolmitriptan could be a better option for acute treatment of 
migraine attacks compared to the available conventional dosage forms. 
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INTRODUCTION 
 Fast dissolving films are most advanced form of solid oral 
dosage form due to its flexibility. It improve efficacy of active 
pharmaceutical ingredient (API) by dissolving in the short 
time in oral cavity after the contact with less amount of 
saliva as compared to mouth dissolving tablet. The oral 
cavity covers the cheek, lips, tongue, hard palate and soft 
palate. The lining of the oral cavity is referred to as the oral 
mucosa. [1]The delivery system is simply placed on the 
patient tongue or any oromucosal tissue. Instantly wet by 
saliva due to the  presence  of  hydrophilic  polymer,  the  film  
rapidly  hydrates  and  dissolves  to  release  the  medication  
for oromucosal absorption.[2] Migraine attacks typically 
unfold through a sequence of events that occur over the time 
course of several hours to days, and typically progresses 
through four phases.[3] Treatment for migraine headaches 
can be divided into two broad categories, acute treatments 
that are taken once a migraine begins, in order to reduce the 
intensity or abort the attack. The objective of the study is to 
develop oral fast dissolving films (OFDF’s) for Zolmitriptan 
in order to improve the bioavailability.[4] Zolmitriptan Oral 
Fast Dissolving Films (ZOFDF’s) is systemically optimized 
using full factorial design. 
Objective 
The aim of preparing fast dissolving oral film of drug 
zolmitriptan was to have better Bioavability, quick onset of 
action (quick relief) and to prevent first pass metabolism.   
MATERIALS 
Zolmitriptan was obtained as a gift sample from Angel 
Biopharma, Ahmedabad, India.   PVA, maltodextrin, HPMC 
and polymers were purchased from S.D. Fine Chem Ltd, 
India. All other chemicals used were analytical grade and 
were used without purification. Double distilled water was 
used in the study. 
METHOD 
Fast dissolving oral films were prepared by using a 
combination of polymers by solvent casting technique. The 
formulations were prepared. The hydrophilic polymers 
namely Maltodextrin (MD) and Polyvinylalchol (PVA), HPMC  
were accurately weighed and dissolved in distilled water and 
propylene glycol (PG) was added as a plasticizer. Drug and 
other ingredients were added to the polymeric dispersion 
under constant stirring with a magnetic stirrer and the 
resultant homogeneous solution was poured into a petridish. 
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Then the films were dried in an oven at 50ºC for 24 h. The 
dried films were wrapped in a butter paper, covered with an 
aluminum foil and kept in desiccators. 
Evaluation of fast dissolving films 
1.  Appearance, Size and Shape  
The formulated films were checked for their appearance, 
shape and thickness. The thickness of the films was 
determined at two different places using a digimatic 
micrometer for each formulation and mean value was 
calculated. 
2.  Thickness 
The thickness of the film was measured using digital verneir 
calipers. The thickness of each film was determined at six 
different locations and standard deviation was calculated. 
3.  Weight variation 
The patches were subjected to mass variation study by 
individually weighing randomly selected patches. The 
average of five observations of each batch was calculated. 
Such determinations were carried out for each batch. 
4.  Drug Content 
The film of specified area (2×2cm) was cut and put in a 
volumetric flask containing 100 ml of phosphate buffer pH 
6.8. The medium was stirred on a magnetic stirrer for proper 
dissolution for 6 hours. The contents were filtered using 
Whatman filter paper and the filtrate was analyzed by UV 
spectrophotometer (Shimadzu-1800) at 206 nm. The 
experiments were performed in triplicate. 
5.  Folding Endurance 
It was determined by repeatedly folding a small strip of the 
patch (2×2cm) at the same place till it broke. The number of 
times a film can be folded at the same place without breaking 
gave the value of folding endurance. Further, less folding 
endurance value indicates more brittleness.  
6.  Disintegration time 
In-vitro disintegration time was determined visually in a 
petridish containing 25 ml of pH 6.8 phosphate buffer with 
swirling every 10 sec.  The disintegration time is the time 
when the film starts to break or disintegrate.  
7.  In-vitro drug release 
For in-vitro dissolution studies, each film was placed with the 
help of forceps in a 50 ml glass beaker containing 25 ml of 
phosphate buffer pH 6.8. The temperature of the dissolution 
media was maintained at 37±0.5ºC; 50 rpm. During the 
study, 3ml of aliquots were withdrawn at 1, 2, 3, 4, 5, 6, 7, 8, 
9 and 10 minutes and were replaced by fresh buffer. The 
amount of drug release in the media was determined by a 
UV-Visible Spectrophotometer (Shimadzu-1800) at 206 nm. 
8.  Surface PH  
The surface pH of the films was determined in order to 
investigate the possibility of any side effects in vivo. As an 
acidic or alkaline pH may cause irritation to the buccal 
mucosa, it was determined to keep the surface pH as close to 
neutral as possible. A combined glass electrode was used for 
this purpose. The 2 cm X 2 cm film was dissolved in 2 ml of 
distilled water. The pH was measured by bringing the 
electrode in contact with the surface of the film and allowing 
it to equilibrate for 1 minute.  
RESULT AND DISSCUSION 
The prepared films were smooth, transparent, flexible and 
uniform. The films were casted in a 10 cm diameter 
petridish. For evaluation purposes 2 cm2 area was cut from 
it. The thickness of the film , standard deviation values were 
low indicating uniformity in thickness as shown in table 2. It 
was observed that all the batches were uniform in weight 
with no significant difference in the weight of the individual 
formulation from the average value.  Drug content of all the 
formulations was determined using UV-Visible 
spectrophoto- meter. Drug content was found to vary 
86.62±0.50 to 98.14±0.64 % in films. The surface pH of the 
films ranged from 6.52±0.27 to 6.72±0.18. Since the surface 
pH of the films was found to be around the neutral pH, there 
will not be any kind of irritation to the mucosal lining of the 
oral cavity. It was observed that in vitro disintegration time 
varies from 9.33±1.52 to 22.33±0.57 sec for all the 
formulations. In vitro disintegration time of FDFs containing 
PVA and Maltodextin as polymers was affected by the 
thickness of the film.  
 
Table 1: Composition of Zolmitriptan Oral Film 
 
S.No. 
 
Ingredients 
Formulation 
F1 F2 F3 
1 Zolmitriptan (Mg) 20 20 20 
2 HPMC (%) 2 1 2 
3 Propylene Glycol (ml) 1 1 2 
4 Sodium Starch Glycolate (%) 4 5 3 
5 Aspartame (mg) 13 13 13 
6 Water (ml) 10 10 10 
 
Table 2:  Evaluation of Physico-Mechanical Parameters of Fast Dissolving oral Film of Zolmitriptan. 
S.No. Evaluation Parameter Stability Study For Formulation  
F1 F2 F3 
 1. Appearance Transparent Transparent Transparent 
 2. Thickness 0.18±0.006 0.21±0.01 0.22±0.01 
3. Weight Variation  0.080±0.002 0.085±0.003 0.110±0.001 
4. %Drug Content (Sec+/-Sd)) 98.14±0.64 97.57±0.91 86.62±0.50 
5. Floding Endurance (Folds) 344.66±2.5 349.66±1.52 378.33±1.52 
6. Disintegration Time (Sec+/-) 9.33±1.52 19.66±1.15 22.33±0.57 
7. In-Vitro Drug Release 97.72% DR in 10 min 97.47%DR in 10 min 97.31%DR in 10 min 
8. Surface pH 6.59±0.18 6.52±0.27 6.72±0.18 
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CONCLUSION 
So from this study it can be concluded that oral fast 
dissolving film of zolmitriptan was successfully designed. 
Also this formulation was stable for a period of 45 days with 
no significant change in drug content and drug release 
profile. Thus it could be said that the fast dissolving film of 
Zolmitriptan could be a better option for acute treatment of 
migraine attacks compared to the available conventional 
dosage forms. 
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